What's next for Novo Nordisk's anti-obesity drug CagriSema?
A version of this article first appeared in CNBC's Healthy Returns newsletter, bringing the latest healthcare news directly to your…
Health
Discover the Latest Health, Medicine, Nutrition, and Fitness Tips for Women, Men, and Children
Novo Nordisk to cut US list prices for Wegovy and Ozempic by up to 50%
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, on February…
Eli Lilly launches anti-obesity drug Zepbound with one-month dosage
An Eli Lilly & Co. Zepbound injection pen placed in the Brooklyn borough of New York on March 28, 2024.…
Fighting in South Sudan displaces nearly 280,000 people; UN warns of 'perfect storm'
The escalation comes amid growing protection risks for civilians and aid workers, with three aid workers killed between February 7…
Novo Nordisk Shares Fall as Weight Loss Drug Fails to Beat Eli Lilly
The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, November 5, 2025. Nichlas Pollier | Bloomberg | fake images…
More medications should be available over the counter
Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over-the-counter” unless a drug is…
FDA Chief Marty Makary on GLP-1 Copies, Vaccines and China
U.S. Food and Drug Administration (FDA) Commissioner Marty Makary presents a study from The Lancet during an announcement of the…
Kennedy defends Trump's order on glyphosate; MAHA explodes
U.S. Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. speaks and announces new nutrition policies during a…
FDA agrees to review Moderna's flu vaccine application after denial
A researcher works in the laboratory at Moderna's headquarters in Cambridge, Massachusetts, on March 26, 2024. Adam Glanzman | Bloomberg…
FDA chief warns that US is losing ground to China in early drug trials
Food and Drug Administration Commissioner Marty Makary warned that the United States is falling behind China in the early stages…